Schistosoma haematobium infection and morbidity before and after large-scale administration of praziquantel in Burkina Faso.

Abstract

BACKGROUND:

In sub-Saharan Africa, 112 million people are infected with Schistosoma haematobium, with the most intense infections in children 5-15 years old.

METHODS:

We describe a longitudinal epidemiological study that evaluates the relationship between S. haematobium infection and associated morbidity in children before and after the large-scale administration of praziquantel for schistosomiasis and albendazole for soil-transmitted helminths.

RESULTS:

At baseline, higher intensities of S. haematobium infection were observed in children with anemia and/or severe microhematuria, but there was no apparent association between the risk of undernutrition and intensity of S. haematobium infection. Significant reductions in the prevalence and intensity of S. haematobium infection 1 year after treatment were, however, observed. Children who benefited the most from anthelmintic treatment in terms of increased hemoglobin concentrations were those who had anemia at baseline and those with highly positive microhematuria scores at baseline.

CONCLUSIONS:

This study suggests that even a single round of mass chemotherapy can have a substantial impact on S. haematobium infection and its associated morbidity in children.

• Authors: Artemis Koukounari, Albis F Gabrielli, Seydou Toure, Elisa Bosque-Oliva, Yaobi Zhang, Bertrand Sellin, Christl A Donnelly, Alan Fenwick, Joanne P Webster
• Journal: The Journal of infectious diseases (J Infect Dis) Vol. 196 Issue 5 Pg. 659-69 (Sep 01 2007) ISSN: 0022-1899 [Print] United States
• PMID: 17674306 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Schistosomicides
• Praziquantel

Topics

• Adolescent
• Anemia
• Burkina Faso (epidemiology)
• Child
• Child, Preschool
• Cohort Studies
• Feces (parasitology)
• Female
• Humans
• Longitudinal Studies
• Male
• Praziquantel (therapeutic use)
• Schistosomiasis haematobia (complications, drug therapy, epidemiology)
• Schistosomicides (therapeutic use)